Adefovir

Summary

Adefovir (CHEMBL484) is an approved small-molecule HIV-1 reverse transcriptase inhibitor; indicated across 3 conditions including chronic hepatitis b virus infection and hepatitis b virus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 40
• Chemistry: 273.19 Da · C8H12N5O4P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL484
Name	Adefovir
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	60172
ChEBI	CHEBI:2469
Molecular formula	C8H12N5O4P
Molecular weight	273.19
InChIKey	SUPKOOSCJHTBAH-UHFFFAOYSA-N

SMILES: C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N

IUPAC name: 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid

ChEBI definition: A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.

Pharmacological roles (ChEBI): HIV-1 reverse transcriptase inhibitor, antiviral drug, nephrotoxic agent, DNA synthesis inhibitor.

Other ChEBI roles (chemical / environmental): drug metabolite.

Also known as: Adefovir, GS 0393, GS-0393, GS0393, adefovir, SID29216223, ADEFOVIR, SID144205435, AdefovirÊ, AdefovirÂ

Parent form; salt/anhydrous children: CHEMBL2386204

Patent coverage: 6,230 distinct patent families (21,676 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 21,153 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Solute carrier family 22 member 6, Fibroblast growth factor receptor 1, Capsid scaffolding protein.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic hepatitis B virus infection	3	MONDO:0005366	EFO:0004239
hepatitis B virus infection	3	MONDO:0005344	EFO:0004197
HIV infectious disease	1	MONDO:0005109	EFO:0000764

Clinical trials

Total trials: 40.

Phase distribution

Phase	Trials
PHASE4	20
PHASE3	9
PHASE2	6
PHASE1	4
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00409019	PHASE4	WITHDRAWN	Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy
NCT00718887	PHASE4	COMPLETED	Suboptimal Responders to Adefovir Switching to Entecavir
NCT00798460	PHASE4	TERMINATED	Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients
NCT00922207	PHASE4	COMPLETED	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
NCT00986778	PHASE4	WITHDRAWN	Entecavir Plus Adefovir in Lamivudine-Resistant Patients
NCT01023217	PHASE4	COMPLETED	Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
NCT01086085	PHASE4	COMPLETED	A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
NCT01088009	PHASE4	COMPLETED	Efficacy Optimizing Research of Lamivudine Therapy
NCT01263002	PHASE4	COMPLETED	A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC
NCT01264133	PHASE4	TERMINATED	A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B
NCT01341743	PHASE4	UNKNOWN	Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy
NCT01546116	PHASE4	COMPLETED	Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)
NCT01693679	PHASE4	UNKNOWN	Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis
NCT01799486	PHASE4	UNKNOWN	Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial
NCT01829685	PHASE4	UNKNOWN	Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy
NCT01834508	PHASE4	UNKNOWN	3E Extension Study
NCT02482272	PHASE4	UNKNOWN	Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B
NCT02560649	PHASE4	UNKNOWN	An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients
NCT02743260	PHASE4	COMPLETED	Drug Transporter Interaction Study PHENTRA_2015_KPUK
NCT03084250	PHASE4	UNKNOWN	The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
NCT00065507	PHASE3	COMPLETED	Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
NCT00096785	PHASE3	COMPLETED	Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
NCT00410202	PHASE3	COMPLETED	Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
NCT00496002	PHASE3	TERMINATED	Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
NCT00496158	PHASE3	TERMINATED	Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
NCT00605384	PHASE3	TERMINATED	A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection
NCT00640588	PHASE3	COMPLETED	Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine
NCT01192854	PHASE3	COMPLETED	An Study of Efficacy and Safety of Clevudine
NCT02366247	PHASE3	UNKNOWN	Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B
NCT00013702	PHASE2	COMPLETED	Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients
NCT00023309	PHASE2	COMPLETED	Lamivudine and Adefovir to Treat Chronic Hepatitis B
NCT00230490	PHASE2	TERMINATED	Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201
NCT00230503	PHASE2	COMPLETED	Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B
NCT00960518	PHASE2	UNKNOWN	TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)
NCT02366208	PHASE2	COMPLETED	Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B
NCT00002115	PHASE1	COMPLETED	A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.
NCT00002326	PHASE1	COMPLETED	The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients
NCT00513968	PHASE1	COMPLETED	Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine
NCT03801759	PHASE1	COMPLETED	Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
NCT01863589	Not specified	COMPLETED	Drug Use Investigation for HEPSERA (Adefovir) Tablet

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).